整形外科重建产品市场－全球产业规模、份额、趋势、机会及预测（依产品、应用、最终用途、地区及竞争格局划分，2021-2031年）

全球整形外科重建产品市场预计将从 2025 年的 52.5 亿美元成长到 2031 年的 69.6 亿美元，复合年增长率为 4.81%。

此领域涵盖生物工程解决方案，例如合成骨替代物、细胞疗法和生长因子，旨在修復、替换和再生受损的肌肉骨骼组织，包括软骨、骨骼和肌腱。推动该领域成长的主要因素是全球骨关节炎盛行率的不断上升以及人口老化趋势，这需要采用组织保护性治疗方法来维持患者的活动能力。为了佐证这项需求，美国整形外科学会 (AAOS) 2024 年年会上公布的数据预测，到 2040 年，老年人运动相关整形外科损伤将增加 123%，凸显了对有效修復干预措施日益增长的需求。

儘管临床需求旺盛，但由于报销体係不统一和病患自付费用高昂，市场面临许多障碍。许多公共和私人保险公司仍然将各种再生医学药物归类为「研究性」或「实验性」药物，这阻碍了患者获得这些药物，并造成了经济障碍，使得这些产品难以被广泛纳入标准医疗实践。

市场驱动因素

组织工程和生物材料领域的技术创新正在透过引入比传统合成植入更有效的先进生物活性支架和细胞疗法，改变整个产业。这些进步，尤其是在软骨修復和皮肤替代物领域，正在克服捐赠者组织短缺的问题，并显着缩短恢復时间，从而促进其在临床环境中的快速应用。这些生物解决方案的商业性影响在自体细胞免疫疗法领域领导者的财务表现中显而易见。例如，Vericel公司在2024年11月发布的2024年第三季财务报告中显示，其软骨修復产品MACI的净销售额达到4,470万美元，年成长19%，凸显了组织工程产品在标准治疗中日益广泛的应用。

同时，运动相关伤害和各种其他伤害的发生率不断上升，推动了再生医学产品在活跃人群（从职业运动员到老年人）恢復功能方面的需求。随着高强度运动参与度的提高，韧带断裂、肌腱损伤和软组织损伤的发生率也随之上升，促使人们研发能够促进自然癒合的生物活性植入。这一趋势支撑着拥有强大运动医学产品组合的製造商（尤其是那些采用生物引导技术的製造商）的稳定收入成长。例如，史密斯医疗（Smith & Nephew）于2024年10月发布的2024年第三季交易报告显示，其运动医学和耳鼻喉科（ENT）部门的营收成长了3.9%，这体现了该市场的强劲势头。此外，史赛克（Stryker）宣布，其整形外科和脊椎部门仅在2024年第三季的净销售额就成长了10.7%，达到23亿美元。

市场挑战

全球整形外科再生医学产品市场​​的扩张主要受制于限制性强且波动较大的医保报销环境。无论是公共医疗机构还是私人医疗机构，通常都将包括细胞注射剂和合成支架在内的再生医学疗法归类为研究性疗法而非医疗必需疗法，导致医保覆盖范围有限，迫使医疗机构要么应对繁琐的核准流程，要么将成本转嫁给患者。因此，儘管这些疗法具有临床吸引力，但由于未报销治疗带来的巨大财务风险，医院仍然不愿意储备这些昂贵的生物製药。

这种财务摩擦直接限制了市场规模，因为它会造成行政障碍，延误或阻止治疗方案的实施。这些障碍的规模相当显着；美国医学会 (AMA) 报告称，到 2024 年，27% 的医生将频繁遭遇预先核准申请被拒的情况。这项挑战对需要详细理由说明的新型治疗方法影响尤为严重。当支付方持续拒绝理赔或强制要求高额自付费用时，患者的接受度就会降低，从而限制製造商的获利潜力，并减缓整个行业的商业性发展。

市场趋势

微创再生医学手术的趋势正在从根本上重塑肌肉骨骼护理，将复杂的治疗从住院机构转移到门诊手术中心（ASC）。这项转变得益于高解析度关节镜和可注射骨生物製药的结合，使外科医生能够植入生物活性基质，从而减少组织损伤并加快恢復速度。这种营运模式转变的商业性成功体现在专注于先进整形外科服务的门诊机构的扩张上。值得注意的是，在2024年11月的第三季财报电话会议上， 果冻 Partners宣布其门诊手术中心的全关节置换术数量年增超过50%，显示手术量正迅速向高效的门诊再生医学模式转变。

同时，羊膜和胎盘组织同种异体移植的应用日益广泛，成为自体组织采集的可行替代方案。它们富含抗发炎细胞激素，是一种即用型解决方案。与需要额外手术部位进行组织采集的自体组织采集方法不同，这些同种异体移植能够即时释放生物讯号，抑制疤痕形成，促进癒合，适用于从肌腱修復到脊椎融合手术等多种手术。市场对胎盘衍生生质材料公司的财务表现也印证了这一点。例如，MiMedx集团在2024年10月发布的「2024年第三季营运与财务业绩」报告中指出，其胎盘组织产品的净销售额达到8,400万美元，这主要得益于其专业外科产品线的贡献成长。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球整形外科与重建外科产品市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（同种异体移植、黏弹性替代物、合成材料、细胞基材料）
  • 按应用领域（整形外科疼痛管理、创伤修復、软骨和肌腱修復、关节重组等）
  • 依最终用途（医院、门诊手术中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美整形外科和重建产品市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲整形外科和重建产品市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区整形外科及重建产品市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东及非洲整形外科及重建外科产品市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲整形外科与重建产品市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球整形外科重建产品市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zimmer Biomet Holdings Inc.
• Baxter International Inc.
• Stryker Corporation
• Smith+Nephew Plc
• AMillioniox Medical, Inc.
• Vericel Corporation
• Anika Therapeutics, Inc.
• Aptissen SA
• Vsy Biotechnology GmbH
• Enovis Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Orthopedic Regenerative Surgical Products Market is projected to expand from USD 5.25 Billion in 2025 to USD 6.96 Billion by 2031, exhibiting a compound annual growth rate of 4.81%. This sector includes biologically engineered solutions such as synthetic bone substitutes, cellular therapies, and growth factors aimed at repairing, replacing, or regenerating damaged musculoskeletal tissues like cartilage, bone, and tendons. Growth is primarily underpinned by the increasing global prevalence of osteoarthritis and the demographic shift toward an aging population necessitating tissue-preserving treatments to sustain mobility. Reinforcing this demand, data presented at the 2024 annual meeting of the American Academy of Orthopaedic Surgeons forecasted a 123% rise in sports-related orthopedic injuries among the elderly by 2040, highlighting the growing need for effective restorative interventions.

Despite strong clinical demand, the market encounters significant obstacles due to inconsistent reimbursement structures and substantial out-of-pocket expenses. Numerous public and private insurers persist in labeling various regenerative therapies as investigational or experimental, establishing financial barriers that hinder patient access and constrain the broad integration of these products into standard medical practice.

Market Driver

Technological innovations in tissue engineering and biomaterials are transforming the industry by introducing advanced biologically active scaffolds and cellular therapies that integrate more effectively than traditional synthetic implants. These developments, especially within cartilage repair and skin substitutes, are fostering rapid clinical adoption by overcoming donor tissue shortages and significantly shortening recovery periods. The commercial impact of these biologic solutions is demonstrated by the financial results of major companies in autologous cellular immunotherapies; for instance, Vericel Corporation reported in its Third Quarter 2024 Financial Results in November 2024 that net revenue for its MACI cartilage repair product rose by 19% year-over-year to $44.7 million, highlighting the increasing use of tissue-engineered options in standard care.

Concurrently, the escalating incidence of sports-related injuries and trauma is fueling the demand for regenerative products designed to restore function across active populations, from professional athletes to seniors. As engagement in high-impact activities grows, the prevalence of ligament tears, tendon injuries, and soft tissue trauma has driven the creation of bioactive implants that accelerate natural healing. This trend supports steady revenue growth for manufacturers with strong sports medicine portfolios, particularly those incorporating bio-inductive technologies. Illustrating this market strength, Smith+Nephew's Third Quarter 2024 Trading Report in October 2024 noted a 3.9% revenue increase in its Sports Medicine & ENT segment, while Stryker reported in 2024 that net sales in its Orthopaedics and Spine segment grew by 10.7% to reach $2.3 billion in the third quarter alone.

Market Challenge

The expansion of the global orthopedic regenerative surgical products market is primarily hindered by a restrictive and variable reimbursement environment. Both public and private payers often categorize regenerative treatments, including cell-based injections and synthetic scaffolds, as investigational rather than medically essential, resulting in limited coverage policies that require providers to manage difficult approval procedures or pass costs to patients. As a result, despite clinical appeal, hospitals remain reluctant to stock these expensive biologics due to the substantial financial risk associated with uncompensated care.

This financial friction directly limits market volume by generating administrative hurdles that delay or block treatment administration. The scale of this barrier is significant; the American Medical Association reported in 2024 that 27% of physicians frequently experienced denials for prior authorization requests, a challenge that particularly impacts novel therapies needing detailed justification. When payers consistently reject claims or mandate high out-of-pocket payments, patient uptake slows, effectively limiting the revenue potential for manufacturers and retarding the sector's overall commercial progress.

Market Trends

The trend toward minimally invasive regenerative procedures is fundamentally reshaping musculoskeletal care by moving complex treatments from inpatient hospitals to ambulatory surgery centers (ASCs). This shift is facilitated by combining high-resolution arthroscopy with injectable orthobiologics, enabling surgeons to implant bioactive matrices with reduced tissue disruption and faster recovery times. The commercial success of this operational change is clear in the expansion of outpatient facilities focusing on high-acuity orthopedic services; notably, Surgery Partners stated in their Third Quarter 2024 Earnings Call in November 2024 that total joint replacement cases in their ASCs grew by over 50% year-over-year, demonstrating a rapid movement of surgical volume toward efficient, outpatient regenerative models.

At the same time, the increasing use of amniotic and placental tissue allografts is emerging as a strong alternative to autologous harvesting, providing off-the-shelf solutions abundant in anti-inflammatory cytokines. Unlike autologous methods that require additional surgical sites for tissue collection, these allografts deliver immediate biological signaling to reduce scarring and improve healing in procedures ranging from tendon repair to spinal fusion. Market acceptance is evident in the financial performance of companies specializing in placental-based biomaterials; for example, MiMedx Group, Inc. reported in its Third Quarter 2024 Operating and Financial Results in October 2024 that net sales for its placental tissue products hit $84 million, supported by the rising contribution of its specialized surgical lines.

Key Market Players

• Zimmer Biomet Holdings Inc.
• Baxter International Inc.
• Stryker Corporation
• Smith+Nephew Plc
• AMillioniox Medical, Inc.
• Vericel Corporation
• Anika Therapeutics, Inc.
• Aptissen S.A
• Vsy Biotechnology GmbH
• Enovis Corporation

Report Scope

In this report, the Global Orthopedic Regenerative Surgical Products Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Orthopedic Regenerative Surgical Products Market, By Product

• Allografts
• Viscosupplements
• Synthetic
• Cell-based

Orthopedic Regenerative Surgical Products Market, By Application

• Orthopedic Pain Management
• Trauma Repair
• Cartilage & Tendon Repair
• Joint Reconstruction
• Others

Orthopedic Regenerative Surgical Products Market, By End-use

• Hospitals
• Ambulatory Surgical Centers
• Others

Orthopedic Regenerative Surgical Products Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Orthopedic Regenerative Surgical Products Market.

Available Customizations:

Global Orthopedic Regenerative Surgical Products Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Orthopedic Regenerative Surgical Products Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Allografts, Viscosupplements, Synthetic, Cell-based)
  • 5.2.2. By Application (Orthopedic Pain Management, Trauma Repair, Cartilage & Tendon Repair, Joint Reconstruction, Others)
  • 5.2.3. By End-use (Hospitals, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Orthopedic Regenerative Surgical Products Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Orthopedic Regenerative Surgical Products Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-use
  • 6.3.2. Canada Orthopedic Regenerative Surgical Products Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-use
  • 6.3.3. Mexico Orthopedic Regenerative Surgical Products Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-use

7. Europe Orthopedic Regenerative Surgical Products Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-use
  • 7.3.2. France Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-use
  • 7.3.3. United Kingdom Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-use
  • 7.3.4. Italy Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-use
  • 7.3.5. Spain Orthopedic Regenerative Surgical Products Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-use

8. Asia Pacific Orthopedic Regenerative Surgical Products Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-use
  • 8.3.2. India Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-use
  • 8.3.3. Japan Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-use
  • 8.3.4. South Korea Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-use
  • 8.3.5. Australia Orthopedic Regenerative Surgical Products Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-use

9. Middle East & Africa Orthopedic Regenerative Surgical Products Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Orthopedic Regenerative Surgical Products Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-use
  • 9.3.2. UAE Orthopedic Regenerative Surgical Products Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-use
  • 9.3.3. South Africa Orthopedic Regenerative Surgical Products Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-use

10. South America Orthopedic Regenerative Surgical Products Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Orthopedic Regenerative Surgical Products Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-use
  • 10.3.2. Colombia Orthopedic Regenerative Surgical Products Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-use
  • 10.3.3. Argentina Orthopedic Regenerative Surgical Products Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Orthopedic Regenerative Surgical Products Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zimmer Biomet Holdings Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Baxter International Inc.
• 15.3. Stryker Corporation
• 15.4. Smith+Nephew Plc
• 15.5. AMillioniox Medical, Inc.
• 15.6. Vericel Corporation
• 15.7. Anika Therapeutics, Inc.
• 15.8. Aptissen S.A
• 15.9. Vsy Biotechnology GmbH
• 15.10. Enovis Corporation

16. Strategic Recommendations

17. About Us & Disclaimer